{
  "success": true,
  "decomposedCriteria": [
    {
      "criterionId": "INC_1",
      "originalText": "Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written informed consent and privacy language as per national regulations (e.g., HIPAA Authorization for US sites) must be obtained from the subject or legally authorized representative (if applicable) prior to any study-related procedures.",
      "type": "Inclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion is a single, complex requirement that must be fulfilled before a specific time point. This is modeled as one atomic condition, representing the successful completion of the informed consent process, which is then wrapped in a TEMPORAL node with a BEFORE operator anchored to the start of study procedures.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "1",
        "nodeType": "temporal",
        "temporalConstraint": {
          "operator": "BEFORE",
          "anchor": "any study-related procedures"
        },
        "operand": {
          "nodeId": "1a",
          "nodeType": "atomic",
          "atomicText": "IRB/IEC approved written informed consent and privacy language obtained from subject or legally authorized representative",
          "omopTable": "observation",
          "strategy": "This is a procedural requirement to ensure ethical and legal standards are met before a patient participates in a study. It is verified by site staff and documentation review, not through standard EHR data queries.",
          "clinicalCategory": "diagnostic_confirmation",
          "queryableStatus": "screening_only"
        }
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 24,
        "textSnippet": "Inclusion/Exclusion Criteria:\nInclusion Criteria: \nWaivers to the inclusion criteria will NOT be allowed.\nGeneral Criteria:\n1. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written \ninformed consent and privacy language as per national regulations (e.g., Health Insurance \nPortability and Accountability Act [HIPAA] Authorization for US sites) must be obtained from \nthe subject or legally authorized representative (if applicable) prior to any study-related \nproced...",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "INC_2",
      "originalText": "Subject is considered an adult (e.g., \u2265 18 years of age in the US) according to local regulation at the time of signing the informed consent.",
      "type": "Inclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion is a single demographic requirement for the subject to be an adult at the time of consent. This is represented as a single atomic condition with a numeric constraint on age, evaluated at a specific time point.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "1",
        "nodeType": "atomic",
        "atomicText": "Age >= 18 years at the time of signing informed consent",
        "omopTable": "observation",
        "timeConstraint": "at the time of signing the informed consent",
        "numericConstraintStructured": {
          "value": 18,
          "operator": ">=",
          "unit": "years",
          "parameter": "age"
        },
        "strategy": "Establishes that the subject meets the legal definition of an adult. Age is calculated relative to the date of informed consent. The value of 18 is a common standard but may vary based on local regulations.",
        "clinicalCategory": "demographics",
        "queryableStatus": "fully_queryable"
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 24,
        "textSnippet": "the subject or legally authorized representative (if applicable) prior to any study-related \nprocedures.\n2. Subject is considered an adult (e.g., \u2265 18 years of age in the US) according to local regulation\nat the time of signing the informed consent.\n3. Subject agrees not to participate in another interventional study while on study treatment.",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "INC_3",
      "originalText": "Subject agrees not to participate in another interventional study while on study treatment.",
      "type": "Inclusion",
      "logicOperator": "NOT",
      "decompositionStrategy": "The criterion is a prohibition against a specific action (participating in another interventional study) during a specific timeframe (while on study treatment). This is modeled as a NOT operator wrapping a temporal node, which in turn contains the atomic condition for the prohibited action.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "NOT",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "temporal",
            "temporalConstraint": {
              "operator": "BETWEEN",
              "anchor": "first_dose",
              "anchorEnd": "last_dose"
            },
            "operand": {
              "nodeId": "1a",
              "nodeType": "atomic",
              "atomicText": "Participation in another interventional study",
              "omopTable": "observation",
              "timeConstraint": "while on study treatment",
              "timeFrameStructured": {
                "value": 0,
                "unit": "",
                "operator": "between",
                "relativeEvent": "first_dose"
              },
              "strategy": "Ensures that the study's results are not confounded by other investigational treatments and protects patient safety from potential drug-drug interactions between investigational products.",
              "clinicalCategory": "safety_exclusion",
              "queryableStatus": "requires_manual"
            }
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 24,
        "textSnippet": "at the time of signing the informed consent.\n3. Subject agrees not to participate in another interventional study while on study treatment.\n4. A female subject is eligible to participate if she is not pregnant (negative serum pregnancy test \nat Screening; female subjects with elevated serum beta human chorionic gonadotropin (\u03b2hCG) \nand a demonstrated non-pregnant status through additional testing are eligible) and at least 1 of \nthe following conditions applies:",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "INC_4",
      "originalText": "A female subject is eligible to participate if she is not pregnant (negative serum pregnancy test at Screening; female subjects with elevated serum beta human chorionic gonadotropin (\u03b2hCG) and a demonstrated non-pregnant status through additional testing are eligible) and at least 1 of the following conditions applies:",
      "type": "Inclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion is a top-level AND condition between two main clauses. The first clause, defining non-pregnant status, is itself a complex OR condition: either the pregnancy test is negative (modeled as NOT positive) OR an initially positive test is confirmed to be non-pregnant by further testing. The second clause of the AND is represented by a placeholder atomic, as its specific conditions are not provided in the text.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "AND",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "operator",
            "operator": "OR",
            "operands": [
              {
                "nodeId": "1a",
                "nodeType": "operator",
                "operator": "NOT",
                "operands": [
                  {
                    "nodeId": "1a1",
                    "nodeType": "atomic",
                    "atomicText": "Positive serum pregnancy test",
                    "omopTable": "measurement",
                    "timeConstraint": "at Screening",
                    "timeFrameStructured": {
                      "value": 0,
                      "unit": "",
                      "operator": "during",
                      "relativeEvent": "screening"
                    },
                    "strategy": "Represents an initial negative pregnancy test result, which is logically equivalent to the absence of a positive test.",
                    "clinicalCategory": "demographics",
                    "queryableStatus": "fully_queryable",
                    "clinicalConceptGroup": "pregnancy_status"
                  }
                ]
              },
              {
                "nodeId": "1b",
                "nodeType": "operator",
                "operator": "AND",
                "operands": [
                  {
                    "nodeId": "1b1",
                    "nodeType": "atomic",
                    "atomicText": "Positive serum pregnancy test",
                    "omopTable": "measurement",
                    "timeConstraint": "at Screening",
                    "timeFrameStructured": {
                      "value": 0,
                      "unit": "",
                      "operator": "during",
                      "relativeEvent": "screening"
                    },
                    "strategy": "Represents an initial positive pregnancy test result (elevated serum \u03b2hCG) at the screening visit.",
                    "clinicalCategory": "demographics",
                    "queryableStatus": "fully_queryable",
                    "clinicalConceptGroup": "pregnancy_status"
                  },
                  {
                    "nodeId": "1b2",
                    "nodeType": "atomic",
                    "atomicText": "Demonstrated non-pregnant status through additional testing",
                    "omopTable": "observation",
                    "strategy": "Represents the confirmation of non-pregnant status via subsequent tests (e.g., ultrasound) after an initial positive/elevated \u03b2hCG test.",
                    "clinicalCategory": "demographics",
                    "queryableStatus": "requires_manual",
                    "clinicalConceptGroup": "pregnancy_status"
                  }
                ]
              }
            ]
          },
          {
            "nodeId": "2",
            "nodeType": "atomic",
            "atomicText": "At least one of the other specified conditions applies",
            "omopTable": "observation",
            "strategy": "This is a placeholder representing the second major clause of the eligibility criterion, for which the specific conditions were not provided.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "requires_manual"
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 24,
        "textSnippet": "3. Subject agrees not to participate in another interventional study while on study treatment.\n4. A female subject is eligible to participate if she is not pregnant (negative serum pregnancy test \nat Screening; female subjects with elevated serum beta human chorionic gonadotropin (\u03b2hCG) \nand a demonstrated non-pregnant status through additional testing are eligible) and at least 1 of \nthe following conditions applies:\na. Not a woman of childbearing potential (WOCBP) as defined in Appendix 12.3",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "INC_5",
      "originalText": "Female subject must agree not to breastfeed starting at Screening and throughout the study period, and for 6 months after the final study treatment administration.",
      "type": "Inclusion",
      "logicOperator": "IMPLICATION",
      "decompositionStrategy": "This criterion is a conditional requirement applicable only to female subjects. It is modeled using an IMPLICATION operator: IF the subject is female, THEN they must agree to the specified breastfeeding restrictions. The agreement itself is treated as a single, positive atomic condition that is manually verified.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "IMPLICATION",
        "condition": {
          "nodeId": "1",
          "nodeType": "atomic",
          "atomicText": "Female",
          "omopTable": "person",
          "strategy": "Identifies the population to which the breastfeeding restriction applies.",
          "clinicalCategory": "demographics",
          "queryableStatus": "fully_queryable"
        },
        "requirement": {
          "nodeId": "2",
          "nodeType": "atomic",
          "atomicText": "Agrees not to breastfeed starting at Screening and throughout the study period, and for 6 months after the final study treatment administration",
          "omopTable": "observation",
          "timeConstraint": "The agreement covers the period from Screening until 6 months after the final dose.",
          "strategy": "This ensures infant safety by preventing exposure to the investigational product through breast milk. Compliance is confirmed by reviewing the signed informed consent form.",
          "clinicalCategory": "demographics",
          "queryableStatus": "requires_manual"
        }
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 24,
        "textSnippet": "the final administration of oxaliplatin and 6 months after the final administration of all \nother study drugs.\n5. Female subject must agree not to breastfeed starting at Screening and throughout the study \nperiod, and for 6 months after the final study treatment administration.\n6. Female subject must not donate ova starting at Screening and throughout the study period, and \nfor 9 months after the final administration of oxaliplatin and 6 months after the final \nadministration of all other stu...",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "INC_6",
      "originalText": "Female subject must not donate ova starting at Screening and throughout the study period, and for 9 months after the final administration of oxaliplatin and 6 months after the final administration of all other study drugs.",
      "type": "Inclusion",
      "logicOperator": "IMPLICATION",
      "decompositionStrategy": "The criterion is a conditional requirement that applies only to female subjects, modeled using an IMPLICATION operator. The requirement is a negation (must NOT donate ova) that applies across a union of three distinct time periods, which is modeled as NOT(OR(TimePeriod1, TimePeriod2, TimePeriod3)).",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "IMPLICATION",
        "condition": {
          "nodeId": "1",
          "nodeType": "atomic",
          "atomicText": "Female subject",
          "omopTable": "person",
          "valueConstraint": "gender_concept_id = 8532",
          "strategy": "The requirement to not donate ova applies only to female subjects.",
          "clinicalCategory": "demographics",
          "queryableStatus": "fully_queryable"
        },
        "requirement": {
          "nodeId": "2",
          "nodeType": "operator",
          "operator": "NOT",
          "operands": [
            {
              "nodeId": "2a",
              "nodeType": "operator",
              "operator": "OR",
              "operands": [
                {
                  "nodeId": "2a1",
                  "nodeType": "temporal",
                  "temporalConstraint": {
                    "operator": "BETWEEN",
                    "anchor": "Screening",
                    "anchorEnd": "End of study period"
                  },
                  "operand": {
                    "nodeId": "2a1a",
                    "nodeType": "atomic",
                    "atomicText": "Donate ova",
                    "omopTable": "procedure_occurrence",
                    "strategy": "Prohibition on ova donation during the main study period.",
                    "clinicalCategory": "safety_exclusion",
                    "queryableStatus": "requires_manual",
                    "clinicalConceptGroup": "ova_donation"
                  }
                },
                {
                  "nodeId": "2a2",
                  "nodeType": "temporal",
                  "temporalConstraint": {
                    "operator": "AFTER",
                    "anchor": "final administration of oxaliplatin",
                    "value": 9,
                    "unit": "months"
                  },
                  "operand": {
                    "nodeId": "2a2a",
                    "nodeType": "atomic",
                    "atomicText": "Donate ova",
                    "omopTable": "procedure_occurrence",
                    "strategy": "Prohibition on ova donation for a specific period after receiving oxaliplatin.",
                    "clinicalCategory": "safety_exclusion",
                    "queryableStatus": "requires_manual",
                    "clinicalConceptGroup": "ova_donation"
                  }
                },
                {
                  "nodeId": "2a3",
                  "nodeType": "temporal",
                  "temporalConstraint": {
                    "operator": "AFTER",
                    "anchor": "final administration of all other study drugs",
                    "value": 6,
                    "unit": "months"
                  },
                  "operand": {
                    "nodeId": "2a3a",
                    "nodeType": "atomic",
                    "atomicText": "Donate ova",
                    "omopTable": "procedure_occurrence",
                    "strategy": "Prohibition on ova donation for a specific period after receiving any other study drug.",
                    "clinicalCategory": "safety_exclusion",
                    "queryableStatus": "requires_manual",
                    "clinicalConceptGroup": "ova_donation"
                  }
                }
              ]
            }
          ]
        }
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 24,
        "textSnippet": "period, and for 6 months after the final study treatment administration.\n6. Female subject must not donate ova starting at Screening and throughout the study period, and \nfor 9 months after the final administration of oxaliplatin and 6 months after the final \nadministration of all other study drugs.\n7. A sexually active male subject with female partner(s) who are of childbearing potential must \nagree to use contraception as detailed in Appendix 12.3 Contraception Requirements during \nthe trea...",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "INC_7",
      "originalText": "A sexually active male subject with female partner(s) who are of childbearing potential must agree to use contraception as detailed in Appendix 12.3 Contraception Requirements during the treatment period and for at least 6 months after the final study drug administration.",
      "type": "Inclusion",
      "logicOperator": "IMPLICATION",
      "decompositionStrategy": "The criterion is a conditional requirement, best modeled using an IMPLICATION operator. The condition (IF part) is that a subject is a sexually active male with female partner(s) of childbearing potential, which is an AND of three distinct demographic/behavioral states. The requirement (THEN part) is the agreement to use contraception for a specified duration, which is a single atomic condition documented at screening.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "IMPLICATION",
        "condition": {
          "nodeId": "1",
          "nodeType": "operator",
          "operator": "AND",
          "operands": [
            {
              "nodeId": "1a",
              "nodeType": "atomic",
              "atomicText": "Male subject",
              "omopTable": "person",
              "strategy": "Identifies the subject's sex as male.",
              "clinicalCategory": "demographics",
              "queryableStatus": "fully_queryable"
            },
            {
              "nodeId": "1b",
              "nodeType": "atomic",
              "atomicText": "Sexually active",
              "omopTable": "observation",
              "strategy": "Identifies if the subject is sexually active, a prerequisite for contraception requirements. This is typically self-reported.",
              "clinicalCategory": "demographics",
              "queryableStatus": "requires_manual"
            },
            {
              "nodeId": "1c",
              "nodeType": "atomic",
              "atomicText": "Has female partner(s) of childbearing potential",
              "omopTable": "observation",
              "strategy": "Identifies if the subject's partner(s) are WOCBP, as this determines the risk of pregnancy. This is self-reported information about a non-participant.",
              "clinicalCategory": "demographics",
              "queryableStatus": "requires_manual"
            }
          ]
        },
        "requirement": {
          "nodeId": "2",
          "nodeType": "atomic",
          "atomicText": "Agrees to use a condom during the treatment period and for at least 6 months after the final study drug administration",
          "omopTable": "observation",
          "timeConstraint": "during the treatment period and for at least 6 months after the final study drug administration",
          "strategy": "Confirms and documents the subject's agreement to adhere to protocol-specified contraception methods and duration to prevent potential fetal exposure to the study drug. This is captured during the informed consent process.",
          "clinicalCategory": "safety_exclusion",
          "queryableStatus": "screening_only"
        }
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 24,
        "textSnippet": "for 9 months after the final administration of oxaliplatin and 6 months after the final \nadministration of all other study drugs.\n7. A sexually active male subject with female partner(s) who are of childbearing potential must \nagree to use contraception as detailed in Appendix 12.3 Contraception Requirements during \nthe treatment period and for at least 6 months after the final study drug administration. \n8. Male subject must not donate sperm starting at Screening and throughout the study per...",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "INC_8",
      "originalText": "Male subject must not donate sperm starting at Screening and throughout the study period and for 6 months after the final study drug administration.",
      "type": "Inclusion",
      "logicOperator": "IMPLICATION",
      "decompositionStrategy": "The criterion is a conditional requirement applicable only to male subjects, which is best modeled using an IMPLICATION operator. The condition is 'subject is male'. The requirement is a prohibition, 'must not donate sperm', which is captured using a NOT operator wrapping the positive action 'Sperm donation'. This prohibition applies over a specific, continuous time period, which is represented by a temporal BETWEEN node.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "IMPLICATION",
        "condition": {
          "nodeId": "1",
          "nodeType": "atomic",
          "atomicText": "Sex is Male",
          "omopTable": "person",
          "strategy": "This criterion applies only to male subjects.",
          "clinicalCategory": "demographics",
          "queryableStatus": "fully_queryable"
        },
        "requirement": {
          "nodeId": "2",
          "nodeType": "operator",
          "operator": "NOT",
          "operands": [
            {
              "nodeId": "2a",
              "nodeType": "temporal",
              "temporalConstraint": {
                "operator": "BETWEEN",
                "anchor": "Screening",
                "anchorEnd": "6 months after final study drug administration"
              },
              "operand": {
                "nodeId": "2a1",
                "nodeType": "atomic",
                "atomicText": "Sperm donation",
                "omopTable": "observation",
                "strategy": "Ensures no risk of conception with sperm potentially affected by the study drug during the study and for a washout period.",
                "clinicalCategory": "safety_exclusion",
                "queryableStatus": "requires_manual"
              }
            }
          ]
        }
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 24,
        "textSnippet": "agree to use contraception as detailed in Appendix 12.3 Contraception Requirements during \nthe treatment period and for at least 6 months after the final study drug administration. \n8. Male subject must not donate sperm starting at Screening and throughout the study period and \nfor 6 months after the final study drug administration.",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "INC_9",
      "originalText": "Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or for the time partner is breastfeeding throughout the study period and for 6 months after the final study drug administration.",
      "type": "Inclusion",
      "logicOperator": "IMPLICATION",
      "decompositionStrategy": "The criterion is a conditional requirement, best represented by an IMPLICATION operator. The condition (IF part) applies to male subjects whose partner is either pregnant or breastfeeding. The requirement (THEN part) is an agreement to one of two contraception methods for a specified duration.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "IMPLICATION",
        "condition": {
          "nodeId": "1",
          "nodeType": "operator",
          "operator": "AND",
          "operands": [
            {
              "nodeId": "1a",
              "nodeType": "atomic",
              "atomicText": "Subject is male",
              "omopTable": "person",
              "strategy": "Checks the subject's gender.",
              "clinicalCategory": "demographics",
              "queryableStatus": "fully_queryable"
            },
            {
              "nodeId": "1b",
              "nodeType": "operator",
              "operator": "OR",
              "operands": [
                {
                  "nodeId": "1b1",
                  "nodeType": "atomic",
                  "atomicText": "Partner is pregnant",
                  "omopTable": "observation",
                  "strategy": "Patient-reported information about partner's pregnancy status, collected at screening.",
                  "clinicalCategory": "demographics",
                  "queryableStatus": "requires_manual",
                  "clinicalConceptGroup": "partner_status"
                },
                {
                  "nodeId": "1b2",
                  "nodeType": "atomic",
                  "atomicText": "Partner is breastfeeding",
                  "omopTable": "observation",
                  "strategy": "Patient-reported information about partner's breastfeeding status, collected at screening.",
                  "clinicalCategory": "demographics",
                  "queryableStatus": "requires_manual",
                  "clinicalConceptGroup": "partner_status"
                }
              ]
            }
          ]
        },
        "requirement": {
          "nodeId": "2",
          "nodeType": "operator",
          "operator": "OR",
          "operands": [
            {
              "nodeId": "2a",
              "nodeType": "atomic",
              "atomicText": "Agrees to remain abstinent for the required duration",
              "omopTable": "observation",
              "timeConstraint": "Throughout the study period and for 6 months after the final study drug administration",
              "strategy": "Confirmation of agreement documented in the informed consent form.",
              "clinicalCategory": "safety_exclusion",
              "queryableStatus": "screening_only",
              "clinicalConceptGroup": "contraception_agreement"
            },
            {
              "nodeId": "2b",
              "nodeType": "atomic",
              "atomicText": "Agrees to use a condom for the required duration",
              "omopTable": "observation",
              "timeConstraint": "Throughout the study period and for 6 months after the final study drug administration",
              "strategy": "Confirmation of agreement documented in the informed consent form.",
              "clinicalCategory": "safety_exclusion",
              "queryableStatus": "screening_only",
              "clinicalConceptGroup": "contraception_agreement"
            }
          ]
        }
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 25,
        "textSnippet": "9. Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent \nor use a condom for the duration of the pregnancy or for the time partner is \nbreastfeeding throughout the study period and for 6 months after the final study drug \nadministration. \nDisease Specific Criteria:\n10. Subject has histologically confirmed diagnosis of Gastric or GEJ adenocarcinoma. \n11. Subject has radiologically confirmed locally advanced unresectable or metastatic disease within \n28 days p...",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "INC_10",
      "originalText": "Subject has histologically confirmed diagnosis of Gastric or GEJ adenocarcinoma.",
      "type": "Inclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion requires a histologically confirmed diagnosis AND that the diagnosis is one of two types: Gastric adenocarcinoma OR GEJ adenocarcinoma. This is decomposed into an AND operator, with the first operand being the confirmation method and the second being an OR operator for the two specific cancer types.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "AND",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "atomic",
            "atomicText": "Histologically confirmed diagnosis",
            "omopTable": "observation",
            "strategy": "Ensures the diagnosis is confirmed by pathology, which is the gold standard.",
            "clinicalCategory": "diagnostic_confirmation",
            "queryableStatus": "requires_manual"
          },
          {
            "nodeId": "2",
            "nodeType": "operator",
            "operator": "OR",
            "operands": [
              {
                "nodeId": "2a",
                "nodeType": "atomic",
                "atomicText": "Gastric adenocarcinoma",
                "omopTable": "condition_occurrence",
                "strategy": "Identifies patients with the primary disease indication of stomach cancer.",
                "clinicalCategory": "disease_indication",
                "queryableStatus": "fully_queryable",
                "clinicalConceptGroup": "gastric_or_gej_adenocarcinoma"
              },
              {
                "nodeId": "2b",
                "nodeType": "atomic",
                "atomicText": "Gastroesophageal junction (GEJ) adenocarcinoma",
                "omopTable": "condition_occurrence",
                "strategy": "Identifies patients with the primary disease indication of cancer at the gastroesophageal junction.",
                "clinicalCategory": "disease_indication",
                "queryableStatus": "fully_queryable",
                "clinicalConceptGroup": "gastric_or_gej_adenocarcinoma"
              }
            ]
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 25,
        "textSnippet": "breastfeeding throughout the study period and for 6 months after the final study drug \nadministration. \nDisease Specific Criteria:\n10. Subject has histologically confirmed diagnosis of Gastric or GEJ adenocarcinoma. \n11. Subject has radiologically confirmed locally advanced unresectable or metastatic disease within \n28 days prior to randomization.",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "INC_11",
      "originalText": "Subject has radiologically confirmed locally advanced unresectable or metastatic disease within 28 days prior to randomization.",
      "type": "Inclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion is a single complex condition with a temporal constraint. I'll model this with a temporal node wrapping an AND/OR structure for the disease confirmation and state.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "1",
        "nodeType": "temporal",
        "temporalConstraint": {
          "operator": "WITHIN",
          "anchor": "randomization",
          "value": 28,
          "unit": "days"
        },
        "operand": {
          "nodeId": "1a",
          "nodeType": "operator",
          "operator": "AND",
          "operands": [
            {
              "nodeId": "1a1",
              "nodeType": "atomic",
              "atomicText": "Disease is radiologically confirmed",
              "omopTable": "observation",
              "timeConstraint": "within 28 days prior to randomization",
              "timeFrameStructured": {
                "value": 28,
                "unit": "days",
                "operator": "within",
                "relativeEvent": "randomization"
              },
              "strategy": "Ensures the disease status is based on objective imaging evidence documented in a report.",
              "clinicalCategory": "diagnostic_confirmation",
              "queryableStatus": "requires_manual"
            },
            {
              "nodeId": "1a2",
              "nodeType": "operator",
              "operator": "OR",
              "operands": [
                {
                  "nodeId": "1a2a",
                  "nodeType": "atomic",
                  "atomicText": "Locally advanced unresectable disease",
                  "omopTable": "condition_occurrence",
                  "strategy": "Identifies patients with advanced disease that cannot be surgically removed, making them candidates for systemic therapy.",
                  "clinicalCategory": "disease_indication",
                  "queryableStatus": "fully_queryable",
                  "clinicalConceptGroup": "advanced_unresectable_or_metastatic_disease"
                },
                {
                  "nodeId": "1a2b",
                  "nodeType": "atomic",
                  "atomicText": "Metastatic disease",
                  "omopTable": "condition_occurrence",
                  "strategy": "Identifies patients whose cancer has spread to distant parts of the body, a key indication for systemic therapy.",
                  "clinicalCategory": "disease_indication",
                  "queryableStatus": "fully_queryable",
                  "clinicalConceptGroup": "advanced_unresectable_or_metastatic_disease"
                }
              ]
            }
          ]
        }
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 25,
        "textSnippet": "Disease Specific Criteria:\n10. Subject has histologically confirmed diagnosis of Gastric or GEJ adenocarcinoma. \n11. Subject has radiologically confirmed locally advanced unresectable or metastatic disease within \n28 days prior to randomization. \n12. Subject has radiologically evaluable disease (measurable and/or non-measurable disease \naccording to RECIST 1.1), per local assessment, \u2264 28 days prior to randomization. For subjects \nwith only 1 evaluable lesion and prior radiotherapy \u2264 3 months...",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "INC_12",
      "originalText": "Subject has radiologically evaluable disease (measurable and/or non-measurable disease according to RECIST 1.1), per local assessment, \u2264 28 days prior to randomization. For subjects with only 1 evaluable lesion and prior radiotherapy \u2264 3 months before randomization, the lesion must either be outside the field of prior radiotherapy or have documented progression following radiation therapy.",
      "type": "Inclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion consists of two main parts connected by AND logic. The first part is a mandatory requirement for radiologically evaluable disease within a specific timeframe. The second part is a conditional (IMPLICATION) requirement that applies only to a specific subset of subjects (those with a single lesion and recent radiotherapy), imposing further constraints on that lesion.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "AND",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "temporal",
            "temporalConstraint": {
              "operator": "WITHIN",
              "anchor": "randomization",
              "value": 28,
              "unit": "days"
            },
            "operand": {
              "nodeId": "1a",
              "nodeType": "atomic",
              "atomicText": "Radiologically evaluable disease (measurable and/or non-measurable disease according to RECIST 1.1), per local assessment",
              "omopTable": "observation",
              "timeConstraint": "\u2264 28 days prior to randomization",
              "timeFrameStructured": {
                "value": 28,
                "unit": "days",
                "operator": "within",
                "relativeEvent": "randomization"
              },
              "strategy": "Confirm presence of evaluable disease via imaging assessment close to the randomization date.",
              "clinicalCategory": "diagnostic_confirmation",
              "queryableStatus": "requires_manual"
            }
          },
          {
            "nodeId": "2",
            "nodeType": "operator",
            "operator": "IMPLICATION",
            "condition": {
              "nodeId": "2_condition",
              "nodeType": "operator",
              "operator": "AND",
              "operands": [
                {
                  "nodeId": "2a",
                  "nodeType": "atomic",
                  "atomicText": "Subject has only 1 evaluable lesion",
                  "omopTable": "observation",
                  "strategy": "Identify subjects with a single site of evaluable disease, who may have had localized therapy.",
                  "clinicalCategory": "disease_indication",
                  "queryableStatus": "requires_manual"
                },
                {
                  "nodeId": "2b",
                  "nodeType": "temporal",
                  "temporalConstraint": {
                    "operator": "WITHIN",
                    "anchor": "randomization",
                    "value": 3,
                    "unit": "months"
                  },
                  "operand": {
                    "nodeId": "2b1",
                    "nodeType": "atomic",
                    "atomicText": "History of radiotherapy",
                    "omopTable": "procedure_occurrence",
                    "timeConstraint": "\u2264 3 months before randomization",
                    "timeFrameStructured": {
                      "value": 3,
                      "unit": "months",
                      "operator": "within",
                      "relativeEvent": "randomization"
                    },
                    "strategy": "Identify subjects who received radiotherapy recently, which could affect the interpretation of the single lesion.",
                    "clinicalCategory": "prior_therapy",
                    "queryableStatus": "fully_queryable"
                  }
                }
              ]
            },
            "requirement": {
              "nodeId": "2_requirement",
              "nodeType": "operator",
              "operator": "OR",
              "operands": [
                {
                  "nodeId": "2c",
                  "nodeType": "atomic",
                  "atomicText": "The evaluable lesion is outside the field of prior radiotherapy",
                  "omopTable": "observation",
                  "strategy": "Ensure the single lesion was not the target of the recent radiotherapy, making it evaluable for trial purposes.",
                  "clinicalCategory": "diagnostic_confirmation",
                  "queryableStatus": "requires_manual"
                },
                {
                  "nodeId": "2d",
                  "nodeType": "atomic",
                  "atomicText": "The evaluable lesion has documented progression following radiation therapy",
                  "omopTable": "observation",
                  "strategy": "Confirm that if the lesion was irradiated, it has since clearly progressed, making it a valid site of active disease.",
                  "clinicalCategory": "prior_therapy",
                  "queryableStatus": "requires_manual"
                }
              ]
            }
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 25,
        "textSnippet": "11. Subject has radiologically confirmed locally advanced unresectable or metastatic disease within \n28 days prior to randomization. \n12. Subject has radiologically evaluable disease (measurable and/or non-measurable disease \naccording to RECIST 1.1), per local assessment, \u2264 28 days prior to randomization. For subjects \nwith only 1 evaluable lesion and prior radiotherapy \u2264 3 months before randomization, the lesion \nmust either be outside the field of prior radiotherapy or have documented prog...",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "INC_13",
      "originalText": "Subject\u2019s tumor expresses CLDN18.2 in \u2265 75% of tumor cells demonstrating moderate to strong membranous staining as determined by central IHC testing.",
      "type": "Inclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion describes a single, multi-faceted biomarker requirement. I have decomposed this into an AND-connected set of atomic conditions, each representing a specific attribute of the required IHC test result: the biomarker identity (CLDN18.2), the quantitative threshold (\u2265 75% cells), the qualitative intensity (moderate to strong staining), and the procedural standard (central testing).",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "AND",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "atomic",
            "atomicText": "Tumor expresses CLDN18.2",
            "omopTable": "measurement",
            "valueConstraint": "Positive",
            "strategy": "Identifies the required target biomarker (Claudin 18.2) for the therapeutic agent.",
            "clinicalCategory": "biomarker",
            "queryableStatus": "requires_manual",
            "clinicalConceptGroup": "cldn18_2_status"
          },
          {
            "nodeId": "2",
            "nodeType": "atomic",
            "atomicText": "CLDN18.2 expression in >= 75% of tumor cells",
            "omopTable": "measurement",
            "numericConstraintStructured": {
              "value": 75,
              "operator": ">=",
              "unit": "%",
              "parameter": "CLDN18.2 positive tumor cells"
            },
            "strategy": "Sets the quantitative threshold for the percentage of tumor cells that must express the biomarker.",
            "clinicalCategory": "biomarker",
            "queryableStatus": "requires_manual",
            "clinicalConceptGroup": "cldn18_2_status"
          },
          {
            "nodeId": "3",
            "nodeType": "atomic",
            "atomicText": "CLDN18.2 demonstrates moderate to strong membranous staining",
            "omopTable": "measurement",
            "valueConstraint": "staining intensity in ['moderate', 'strong'] and location is 'membranous'",
            "strategy": "Defines the required qualitative intensity and cellular location of the biomarker staining for eligibility.",
            "clinicalCategory": "biomarker",
            "queryableStatus": "requires_manual",
            "clinicalConceptGroup": "cldn18_2_status"
          },
          {
            "nodeId": "4",
            "nodeType": "atomic",
            "atomicText": "CLDN18.2 status determined by central IHC testing",
            "omopTable": "observation",
            "strategy": "Ensures the reliability and standardization of the biomarker assessment by mandating it be performed by a central laboratory using an Immunohistochemistry (IHC) assay.",
            "clinicalCategory": "diagnostic_confirmation",
            "queryableStatus": "requires_manual",
            "clinicalConceptGroup": "cldn18_2_status"
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 25,
        "textSnippet": "must either be outside the field of prior radiotherapy or have documented progression following \nradiation therapy.\n13. Subject\u2019s tumor expresses CLDN18.2 in \u2265 75% of tumor cells demonstrating moderate to strong \nmembranous staining as determined by central IHC testing.\n14. Subject has a HER2-negative tumor as determined by local or central testing on a gastric or \nGEJ tumor specimen. (Unique to China: Subject has a known HER2-negative gastric or GEJ \ntumor).",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "INC_14",
      "originalText": "Subject has a known HER2-negative tumor as determined by local or central testing on a gastric or GEJ tumor specimen. (Unique to China: Subject has a known HER2-negative gastric or GEJ tumor.)",
      "type": "Inclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion is decomposed into a set of AND conditions: the tumor must be HER2-negative, the tumor type must be gastric OR GEJ, and this status must be confirmed by a valid test. The parenthetical note for China is considered a regional clarification rather than a separate logical path, as its components are covered by the main clause.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "AND",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "atomic",
            "atomicText": "HER2-negative tumor status",
            "omopTable": "measurement",
            "valueConstraint": "Result is 'Negative' or equivalent concept for HER2 test",
            "strategy": "Identifies patients whose tumor has been tested and found to be negative for HER2 overexpression or gene amplification.",
            "clinicalCategory": "biomarker",
            "queryableStatus": "fully_queryable",
            "clinicalConceptGroup": "her2_status"
          },
          {
            "nodeId": "2",
            "nodeType": "operator",
            "operator": "OR",
            "operands": [
              {
                "nodeId": "2a",
                "nodeType": "atomic",
                "atomicText": "Gastric tumor",
                "omopTable": "condition_occurrence",
                "strategy": "Confirms the primary disease is gastric cancer.",
                "clinicalCategory": "disease_indication",
                "queryableStatus": "fully_queryable",
                "clinicalConceptGroup": "primary_tumor_location"
              },
              {
                "nodeId": "2b",
                "nodeType": "atomic",
                "atomicText": "Gastroesophageal junction (GEJ) tumor",
                "omopTable": "condition_occurrence",
                "strategy": "Confirms the primary disease is gastroesophageal junction cancer.",
                "clinicalCategory": "disease_indication",
                "queryableStatus": "fully_queryable",
                "clinicalConceptGroup": "primary_tumor_location"
              }
            ]
          },
          {
            "nodeId": "3",
            "nodeType": "atomic",
            "atomicText": "HER2 status determined on a tumor specimen by local or central testing",
            "omopTable": "observation",
            "strategy": "Ensures the HER2 status is documented from a formal laboratory assessment on an appropriate tissue sample.",
            "clinicalCategory": "diagnostic_confirmation",
            "queryableStatus": "partially_queryable"
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 25,
        "textSnippet": "membranous staining as determined by central IHC testing.\n14. Subject has a HER2-negative tumor as determined by local or central testing on a gastric or \nGEJ tumor specimen. (Unique to China: Subject has a known HER2-negative gastric or GEJ \ntumor).\nPhysical or Laboratory Findings\n15. Subject has ECOG performance status 0 to 1.",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "INC_15",
      "originalText": "Subject has ECOG performance status 0 to 1.",
      "type": "Inclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "This criterion is a single condition specifying a numeric range for a clinical assessment. It is decomposed into a single atomic node with a numericRangeStructured constraint to capture the inclusive range of 0 to 1 for the ECOG performance status.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "1",
        "nodeType": "atomic",
        "atomicText": "ECOG performance status 0-1",
        "omopTable": "observation",
        "numericRangeStructured": {
          "min": 0,
          "max": 1,
          "unit": "",
          "parameter": "ECOG performance status"
        },
        "strategy": "This assesses the subject's functional capacity and ability to perform daily activities. A score of 0-1 indicates the subject is fully active or restricted in strenuous activity but ambulatory.",
        "clinicalCategory": "performance_status",
        "queryableStatus": "fully_queryable"
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 25,
        "textSnippet": "tumor).\nPhysical or Laboratory Findings\n15. Subject has ECOG performance status 0 to 1.\n16. Subject has predicted life expectancy \uf0b3 12 weeks in the opinion of the investigator.\n17. Subject must meet all of the following criteria based on the centrally or locally analyzed \nlaboratory tests collected within 14 days prior to randomization. In the case of multiple sample \ncollections within this period, the most recent sample collection with available results should \nbe used to determine eligibil...",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "INC_16",
      "originalText": "Subject has predicted life expectancy \u2265 12 weeks in the opinion of the investigator.",
      "type": "Inclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion is a single, atomic condition representing a clinical judgment about the subject's prognosis. It is represented as a single atomic node with a numeric constraint.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "1",
        "nodeType": "atomic",
        "atomicText": "Predicted life expectancy \u2265 12 weeks in the opinion of the investigator",
        "omopTable": "observation",
        "numericConstraintStructured": {
          "value": 12,
          "operator": ">=",
          "unit": "weeks",
          "parameter": "predicted life expectancy"
        },
        "strategy": "This is a subjective assessment by the investigator to ensure the subject is likely to survive long enough to be evaluated for the trial's endpoints. It is not directly queryable from structured data.",
        "clinicalCategory": "performance_status",
        "queryableStatus": "requires_manual"
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 25,
        "textSnippet": "Physical or Laboratory Findings\n15. Subject has ECOG performance status 0 to 1.\n16. Subject has predicted life expectancy \uf0b3 12 weeks in the opinion of the investigator.\n17. Subject must meet all of the following criteria based on the centrally or locally analyzed \nlaboratory tests collected within 14 days prior to randomization. In the case of multiple sample \ncollections within this period, the most recent sample collection with available results should \nbe used to determine eligibility. \na....",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "INC_17",
      "originalText": "Subject must meet all of the following criteria based on the centrally or locally analyzed laboratory tests collected within 14 days prior to randomization. In the case of multiple sample collections within this period, the most recent sample collection with available results should be used to determine eligibility.",
      "type": "Inclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "This criterion is a preamble that establishes a temporal constraint for all subsequent laboratory-based criteria. It is decomposed into a single temporal node that requires the relevant laboratory tests to have been collected within a specific time frame relative to randomization. The procedural note about using the most recent sample is captured in the strategy text.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "temporal",
        "temporalConstraint": {
          "operator": "WITHIN",
          "anchor": "randomization",
          "value": 14,
          "unit": "days"
        },
        "operand": {
          "nodeId": "root_a",
          "nodeType": "atomic",
          "atomicText": "Required laboratory tests for eligibility assessment collected",
          "omopTable": "measurement",
          "strategy": "This is a meta-criterion that sets the time window for all subsequent lab-based criteria. It also specifies a procedural rule: if multiple samples were collected in this period, the most recent one with available results must be used for eligibility determination.",
          "clinicalCategory": "diagnostic_confirmation",
          "queryableStatus": "partially_queryable"
        }
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 25,
        "textSnippet": "16. Subject has predicted life expectancy \uf0b3 12 weeks in the opinion of the investigator.\n17. Subject must meet all of the following criteria based on the centrally or locally analyzed \nlaboratory tests collected within 14 days prior to randomization. In the case of multiple sample \ncollections within this period, the most recent sample collection with available results should \nbe used to determine eligibility. \na. Hemoglobin (Hgb) \u2265 9 g/dL. Subjects requiring transfusions are eligible if they...",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_1",
      "originalText": "Subject has received prior systemic chemotherapy for locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma. However, subject may have received either neo-adjuvant or adjuvant chemotherapy, immunotherapy or other systemic anticancer therapies as long as it was completed at least 6 months prior to randomization. Subject may have received treatment with herbal medications that have known antitumor activity > 28 days prior to randomization.",
      "type": "Exclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion is decomposed into a top-level AND structure. The primary requirement is receiving prior systemic chemotherapy for advanced/metastatic disease. The two subsequent 'However' and 'may have received' clauses are conditional allowances, modeled as IMPLICATION operators. These state that IF a subject received other specified therapies (adjuvant/neo-adjuvant/immunotherapy or herbal meds), THEN a specific time constraint on when those therapies were completed must be met. The time constraints 'at least 6 months prior' and '> 28 days prior' are modeled using a NOT(WITHIN) pattern for precision.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "AND",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "atomic",
            "atomicText": "Received prior systemic chemotherapy for locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma",
            "omopTable": "drug_exposure",
            "strategy": "Identifies patients who have received at least one line of systemic chemotherapy for the advanced/metastatic disease setting, establishing them as eligible for a subsequent line of therapy.",
            "clinicalCategory": "prior_therapy",
            "queryableStatus": "partially_queryable"
          },
          {
            "nodeId": "2",
            "nodeType": "operator",
            "operator": "IMPLICATION",
            "condition": {
              "nodeId": "2a",
              "nodeType": "operator",
              "operator": "OR",
              "operands": [
                {
                  "nodeId": "2a1",
                  "nodeType": "atomic",
                  "atomicText": "Received neo-adjuvant or adjuvant chemotherapy",
                  "omopTable": "drug_exposure",
                  "strategy": "Identifies prior therapy in the curative-intent (neo-adjuvant/adjuvant) setting.",
                  "clinicalCategory": "prior_therapy",
                  "queryableStatus": "partially_queryable",
                  "clinicalConceptGroup": "prior_systemic_therapy"
                },
                {
                  "nodeId": "2a2",
                  "nodeType": "atomic",
                  "atomicText": "Received immunotherapy",
                  "omopTable": "drug_exposure",
                  "strategy": "Identifies prior immunotherapy.",
                  "clinicalCategory": "prior_therapy",
                  "queryableStatus": "fully_queryable",
                  "clinicalConceptGroup": "prior_systemic_therapy"
                },
                {
                  "nodeId": "2a3",
                  "nodeType": "atomic",
                  "atomicText": "Received other systemic anticancer therapies",
                  "omopTable": "drug_exposure",
                  "strategy": "Identifies any other prior systemic treatments not otherwise specified.",
                  "clinicalCategory": "prior_therapy",
                  "queryableStatus": "partially_queryable",
                  "clinicalConceptGroup": "prior_systemic_therapy"
                }
              ]
            },
            "requirement": {
              "nodeId": "2b",
              "nodeType": "operator",
              "operator": "NOT",
              "operands": [
                {
                  "nodeId": "2b1",
                  "nodeType": "temporal",
                  "temporalConstraint": {
                    "operator": "WITHIN",
                    "anchor": "randomization",
                    "value": 6,
                    "unit": "months"
                  },
                  "operand": {
                    "nodeId": "2b1a",
                    "nodeType": "atomic",
                    "atomicText": "Completion of neo-adjuvant/adjuvant chemotherapy, immunotherapy, or other systemic anticancer therapy",
                    "omopTable": "observation",
                    "strategy": "Ensures a sufficient washout period from prior systemic therapies received in a non-metastatic setting to avoid confounding effects.",
                    "clinicalCategory": "prior_therapy",
                    "queryableStatus": "partially_queryable"
                  }
                }
              ]
            }
          },
          {
            "nodeId": "3",
            "nodeType": "operator",
            "operator": "IMPLICATION",
            "condition": {
              "nodeId": "3a",
              "nodeType": "atomic",
              "atomicText": "Received treatment with herbal medications that have known antitumor activity",
              "omopTable": "drug_exposure",
              "strategy": "Identifies use of herbal medications with potential anticancer properties.",
              "clinicalCategory": "prior_therapy",
              "queryableStatus": "requires_manual"
            },
            "requirement": {
              "nodeId": "3b",
              "nodeType": "operator",
              "operator": "NOT",
              "operands": [
                {
                  "nodeId": "3b1",
                  "nodeType": "temporal",
                  "temporalConstraint": {
                    "operator": "WITHIN",
                    "anchor": "randomization",
                    "value": 28,
                    "unit": "days"
                  },
                  "operand": {
                    "nodeId": "3b1a",
                    "nodeType": "atomic",
                    "atomicText": "Completion of treatment with herbal medications with known antitumor activity",
                    "omopTable": "observation",
                    "strategy": "Ensures a sufficient washout period from herbal medications to avoid potential drug interactions or confounding biological effects.",
                    "clinicalCategory": "prior_therapy",
                    "queryableStatus": "requires_manual"
                  }
                }
              ]
            }
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 26,
        "textSnippet": "Exclusion Criteria:\nWaivers to the exclusion criteria will NOT be allowed. \nSubject who meets any of the following exclusion criteria prior to enrollment is not eligible for \nenrollment: \nProhibited Treatment or Therapies\n1. Subject has received prior systemic chemotherapy for locally advanced unresectable or \nmetastatic gastric or GEJ adenocarcinoma. However, subject may have received either neo adjuvant or adjuvant chemotherapy, immunotherapy or other systemic anticancer therapies as \nlong ...",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_2",
      "originalText": "Subject has received radiotherapy for locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma \u2264 14 days prior to randomization and has not recovered from any related toxicity.",
      "type": "Exclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion is a conjunction of three conditions: (1) receiving radiotherapy within a specific timeframe, (2) having a specific cancer diagnosis, and (3) not having recovered from radiotherapy-related toxicity. This is modeled as a root AND operator. The complex cancer definition is broken into a nested AND/OR structure, and the non-recovery is captured with a NOT operator.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "AND",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "temporal",
            "temporalConstraint": {
              "operator": "WITHIN",
              "anchor": "randomization",
              "value": 14,
              "unit": "days"
            },
            "operand": {
              "nodeId": "1a",
              "nodeType": "atomic",
              "atomicText": "Received radiotherapy",
              "omopTable": "procedure_occurrence",
              "strategy": "Identifies patients who have undergone radiotherapy. The timeframe is constrained by the parent temporal node.",
              "clinicalCategory": "prior_therapy",
              "queryableStatus": "fully_queryable"
            }
          },
          {
            "nodeId": "2a",
            "nodeType": "operator",
            "operator": "OR",
            "operands": [
              {
                "nodeId": "2a1",
                "nodeType": "atomic",
                "atomicText": "Diagnosis of gastric adenocarcinoma",
                "omopTable": "condition_occurrence",
                "strategy": "Identifies the primary tumor location as gastric cancer.",
                "clinicalCategory": "disease_indication",
                "queryableStatus": "fully_queryable",
                "clinicalConceptGroup": "gastric_gej_adenocarcinoma"
              },
              {
                "nodeId": "2a2",
                "nodeType": "atomic",
                "atomicText": "Diagnosis of gastroesophageal junction (GEJ) adenocarcinoma",
                "omopTable": "condition_occurrence",
                "strategy": "Identifies the primary tumor location as GEJ cancer.",
                "clinicalCategory": "disease_indication",
                "queryableStatus": "fully_queryable",
                "clinicalConceptGroup": "gastric_gej_adenocarcinoma"
              }
            ]
          },
          {
            "nodeId": "2b",
            "nodeType": "operator",
            "operator": "OR",
            "operands": [
              {
                "nodeId": "2b1",
                "nodeType": "atomic",
                "atomicText": "Disease is locally advanced unresectable",
                "omopTable": "observation",
                "strategy": "Identifies patients with disease that is advanced but not yet spread to distant sites and cannot be surgically removed.",
                "clinicalCategory": "disease_indication",
                "queryableStatus": "partially_queryable",
                "clinicalConceptGroup": "disease_stage_unresectable_metastatic"
              },
              {
                "nodeId": "2b2",
                "nodeType": "atomic",
                "atomicText": "Disease is metastatic",
                "omopTable": "condition_occurrence",
                "strategy": "Identifies patients whose cancer has spread to distant parts of the body.",
                "clinicalCategory": "disease_indication",
                "queryableStatus": "fully_queryable",
                "clinicalConceptGroup": "disease_stage_unresectable_metastatic"
              }
            ]
          },
          {
            "nodeId": "3",
            "nodeType": "operator",
            "operator": "NOT",
            "operands": [
              {
                "nodeId": "3a",
                "nodeType": "atomic",
                "atomicText": "Recovered from radiotherapy-related toxicity",
                "omopTable": "observation",
                "strategy": "Identifies the resolution of adverse events related to radiotherapy. The parent NOT operator ensures the patient has not recovered.",
                "clinicalCategory": "safety_exclusion",
                "queryableStatus": "requires_manual"
              }
            ]
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 26,
        "textSnippet": "treatment with herbal medications that have known antitumor activity > 28 days prior to \nrandomization.\n2. Subject has received radiotherapy for locally advanced unresectable or metastatic gastric or \nGEJ adenocarcinoma \u2264 14 days prior to randomization and has not recovered from any related \ntoxicity. \n3. Subject has received systemic immunosuppressive therapy, including systemic corticosteroids \nwithin 14 days prior to randomization. Subjects using a physiologic replacement dose of \nhydrocor...",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_3",
      "originalText": "Subject has received systemic immunosuppressive therapy, including systemic corticosteroids within 14 days prior to randomization. Subjects using a physiologic replacement dose of hydrocortisone or its equivalent (defined as up to 30 mg per day of hydrocortisone or up to 10 mg per day of prednisone), receiving a single dose of systemic corticosteroids or receiving systemic corticosteroids as premedication for radiologic imaging contrast use are allowed.",
      "type": "Exclusion",
      "logicOperator": "EXCEPT",
      "decompositionStrategy": "The criterion is structured as a main exclusion rule with a list of exceptions. This is best modeled using the EXCEPT operator, where the first operand is the broad exclusion condition (immunosuppressive therapy within 14 days) and the second operand is an OR group of all the allowed exceptions (physiologic doses, single doses, or premedication).",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "EXCEPT",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "temporal",
            "temporalConstraint": {
              "operator": "WITHIN",
              "anchor": "randomization",
              "value": 14,
              "unit": "days"
            },
            "operand": {
              "nodeId": "1a",
              "nodeType": "operator",
              "operator": "OR",
              "operands": [
                {
                  "nodeId": "1a1",
                  "nodeType": "atomic",
                  "atomicText": "Received systemic immunosuppressive therapy",
                  "omopTable": "drug_exposure",
                  "strategy": "Identifies subjects who have received any systemic immunosuppressive agents.",
                  "clinicalCategory": "prior_therapy",
                  "queryableStatus": "fully_queryable",
                  "clinicalConceptGroup": "systemic_immunosuppression"
                },
                {
                  "nodeId": "1a2",
                  "nodeType": "atomic",
                  "atomicText": "Received systemic corticosteroids",
                  "omopTable": "drug_exposure",
                  "strategy": "Identifies subjects who have received systemic corticosteroids, which are explicitly included in the exclusion.",
                  "clinicalCategory": "prior_therapy",
                  "queryableStatus": "fully_queryable",
                  "clinicalConceptGroup": "systemic_immunosuppression"
                }
              ]
            }
          },
          {
            "nodeId": "2",
            "nodeType": "operator",
            "operator": "OR",
            "operands": [
              {
                "nodeId": "2a1",
                "nodeType": "atomic",
                "atomicText": "Received hydrocortisone at a physiologic replacement dose up to 30 mg/day",
                "omopTable": "drug_exposure",
                "numericConstraintStructured": {
                  "value": 30,
                  "operator": "<=",
                  "unit": "mg/day",
                  "parameter": "hydrocortisone daily dose"
                },
                "strategy": "Checks for allowed use of hydrocortisone at a low, physiologic dose.",
                "clinicalCategory": "prior_therapy",
                "queryableStatus": "partially_queryable",
                "clinicalConceptGroup": "physiologic_steroid_dose"
              },
              {
                "nodeId": "2a2",
                "nodeType": "atomic",
                "atomicText": "Received prednisone at a physiologic replacement dose up to 10 mg/day",
                "omopTable": "drug_exposure",
                "numericConstraintStructured": {
                  "value": 10,
                  "operator": "<=",
                  "unit": "mg/day",
                  "parameter": "prednisone daily dose"
                },
                "strategy": "Checks for allowed use of prednisone (or equivalent) at a low, physiologic dose.",
                "clinicalCategory": "prior_therapy",
                "queryableStatus": "partially_queryable",
                "clinicalConceptGroup": "physiologic_steroid_dose"
              },
              {
                "nodeId": "2b",
                "nodeType": "atomic",
                "atomicText": "Received a single dose of systemic corticosteroids",
                "omopTable": "drug_exposure",
                "strategy": "Checks for allowed use of a one-time systemic corticosteroid dose.",
                "clinicalCategory": "prior_therapy",
                "queryableStatus": "partially_queryable"
              },
              {
                "nodeId": "2c",
                "nodeType": "atomic",
                "atomicText": "Received systemic corticosteroids as premedication for radiologic imaging contrast use",
                "omopTable": "drug_exposure",
                "strategy": "Checks for allowed use of corticosteroids specifically for contrast premedication, which requires linking drug administration to a procedure.",
                "clinicalCategory": "prior_therapy",
                "queryableStatus": "requires_manual"
              }
            ]
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 26,
        "textSnippet": "GEJ adenocarcinoma \u2264 14 days prior to randomization and has not recovered from any related \ntoxicity. \n3. Subject has received systemic immunosuppressive therapy, including systemic corticosteroids \nwithin 14 days prior to randomization. Subjects using a physiologic replacement dose of \nhydrocortisone or its equivalent (defined as up to 30 mg per day of hydrocortisone or up to 10 \nmg per day of prednisone), receiving a single dose of systemic corticosteroids or receiving \nsystemic corticoster...",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_4",
      "originalText": "Subject has received other investigational agents or devices within 28 days prior to randomization.",
      "type": "Exclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion describes a single condition with a temporal constraint. This is represented by a temporal node ('within 28 days prior to randomization') which contains the core condition. The condition itself ('investigational agents or devices') implies an OR, so it's decomposed into an OR operator with two atomic operands.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "1",
        "nodeType": "temporal",
        "temporalConstraint": {
          "operator": "WITHIN",
          "anchor": "randomization",
          "value": 28,
          "unit": "days"
        },
        "operand": {
          "nodeId": "1a",
          "nodeType": "operator",
          "operator": "OR",
          "operands": [
            {
              "nodeId": "1a1",
              "nodeType": "atomic",
              "atomicText": "Received other investigational agents",
              "omopTable": "drug_exposure",
              "strategy": "Checks for exposure to investigational drugs to prevent confounding effects from other trials.",
              "clinicalCategory": "prior_therapy",
              "queryableStatus": "partially_queryable",
              "clinicalConceptGroup": "investigational_product_exposure"
            },
            {
              "nodeId": "1a2",
              "nodeType": "atomic",
              "atomicText": "Received other investigational devices",
              "omopTable": "device_exposure",
              "strategy": "Checks for exposure to investigational devices to prevent confounding effects from other trials.",
              "clinicalCategory": "prior_therapy",
              "queryableStatus": "partially_queryable",
              "clinicalConceptGroup": "investigational_product_exposure"
            }
          ]
        }
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 26,
        "textSnippet": "systemic corticosteroids as premedication for radiologic imaging contrast use are allowed.\n4. Subject has received other investigational agents or devices within 28 days prior to \nrandomization.\nMedical History or Concurrent Disease\n5. Subject has prior severe allergic reaction or intolerance to known ingredients of zolbetuximab \nor other monoclonal antibodies, including humanized or chimeric antibodies.",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_5",
      "originalText": "Subject has prior severe allergic reaction or intolerance to known ingredients of zolbetuximab or other monoclonal antibodies, including humanized or chimeric antibodies.",
      "type": "Exclusion",
      "logicOperator": "OR",
      "decompositionStrategy": "The criterion describes a set of contraindications based on prior hypersensitivity. The logic is a disjunction (OR) of several related conditions. I have decomposed this into an OR operator with four atomic operands, one for each specific substance or drug class mentioned (zolbetuximab ingredients, other monoclonal antibodies, humanized antibodies, and chimeric antibodies) to ensure each is explicitly accounted for.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "OR",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "atomic",
            "atomicText": "Prior severe allergic reaction or intolerance to known ingredients of zolbetuximab",
            "omopTable": "observation",
            "strategy": "Checks for specific contraindications to the study drug or its components based on documented prior hypersensitivity.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "requires_manual",
            "clinicalConceptGroup": "zolbetuximab_hypersensitivity"
          },
          {
            "nodeId": "2",
            "nodeType": "atomic",
            "atomicText": "Prior severe allergic reaction or intolerance to other monoclonal antibodies",
            "omopTable": "observation",
            "strategy": "Checks for hypersensitivity to the general class of monoclonal antibodies, which may predict a reaction to zolbetuximab.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "partially_queryable",
            "clinicalConceptGroup": "mab_hypersensitivity"
          },
          {
            "nodeId": "3",
            "nodeType": "atomic",
            "atomicText": "Prior severe allergic reaction or intolerance to humanized antibodies",
            "omopTable": "observation",
            "strategy": "Checks for hypersensitivity to humanized antibodies, a specific subclass of monoclonal antibodies mentioned for clarity.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "partially_queryable",
            "clinicalConceptGroup": "mab_hypersensitivity"
          },
          {
            "nodeId": "4",
            "nodeType": "atomic",
            "atomicText": "Prior severe allergic reaction or intolerance to chimeric antibodies",
            "omopTable": "observation",
            "strategy": "Checks for hypersensitivity to chimeric antibodies, another specific subclass of monoclonal antibodies mentioned for clarity.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "partially_queryable",
            "clinicalConceptGroup": "mab_hypersensitivity"
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 26,
        "textSnippet": "randomization.\nMedical History or Concurrent Disease\n5. Subject has prior severe allergic reaction or intolerance to known ingredients of zolbetuximab \nor other monoclonal antibodies, including humanized or chimeric antibodies.\n6. Subject has known immediate or delayed hypersensitivity, intolerance or contraindication to \nany component of study treatment.",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_6",
      "originalText": "Subject has known immediate or delayed hypersensitivity, intolerance or contraindication to any component of study treatment.",
      "type": "Exclusion",
      "logicOperator": "OR",
      "decompositionStrategy": "The criterion lists four related but distinct conditions (immediate hypersensitivity, delayed hypersensitivity, intolerance, contraindication) linked by 'or'. This is decomposed into a root OR operator with four atomic operands, each representing one of these safety-related exclusions.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "OR",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "atomic",
            "atomicText": "Known immediate hypersensitivity to any component of study treatment",
            "omopTable": "condition_occurrence",
            "strategy": "Identifies subjects with a known history of immediate allergic reactions to the study drug or its components to prevent severe adverse events.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "requires_manual",
            "clinicalConceptGroup": "drug_allergy_intolerance_contraindication"
          },
          {
            "nodeId": "2",
            "nodeType": "atomic",
            "atomicText": "Known delayed hypersensitivity to any component of study treatment",
            "omopTable": "condition_occurrence",
            "strategy": "Identifies subjects with a known history of delayed allergic reactions to the study drug or its components to prevent adverse events.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "requires_manual",
            "clinicalConceptGroup": "drug_allergy_intolerance_contraindication"
          },
          {
            "nodeId": "3",
            "nodeType": "atomic",
            "atomicText": "Known intolerance to any component of study treatment",
            "omopTable": "condition_occurrence",
            "strategy": "Identifies subjects who cannot tolerate the study drug due to non-allergic adverse effects, ensuring patient safety and treatment compliance.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "requires_manual",
            "clinicalConceptGroup": "drug_allergy_intolerance_contraindication"
          },
          {
            "nodeId": "4",
            "nodeType": "atomic",
            "atomicText": "Known contraindication to any component of study treatment",
            "omopTable": "condition_occurrence",
            "strategy": "Identifies subjects with pre-existing conditions or factors that make administration of the study drug unsafe.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "requires_manual",
            "clinicalConceptGroup": "drug_allergy_intolerance_contraindication"
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 26,
        "textSnippet": "or other monoclonal antibodies, including humanized or chimeric antibodies.\n6. Subject has known immediate or delayed hypersensitivity, intolerance or contraindication to \nany component of study treatment.\n7. Subject has prior severe allergic reaction or intolerance to any component of mFOLFOX6.",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_7",
      "originalText": "Subject has prior severe allergic reaction or intolerance to any component of mFOLFOX6.",
      "type": "Exclusion",
      "logicOperator": "OR",
      "decompositionStrategy": "The criterion is a disjunction (OR) of two conditions: 'severe allergic reaction' and 'intolerance'. Each condition applies to any of the three components of the mFOLFOX6 regimen (Leucovorin, Fluorouracil, Oxaliplatin). This expands to a single OR operator with six atomic conditions, covering every combination of contraindication and drug component.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "OR",
        "operands": [
          {
            "nodeId": "1a",
            "nodeType": "atomic",
            "atomicText": "Prior severe allergic reaction to Leucovorin",
            "omopTable": "condition_occurrence",
            "timeConstraint": "prior",
            "strategy": "Identifies a history of severe allergy to Leucovorin (folinic acid), a component of the mFOLFOX6 regimen.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "partially_queryable",
            "clinicalConceptGroup": "mfolfox6_leucovorin_contraindication"
          },
          {
            "nodeId": "1b",
            "nodeType": "atomic",
            "atomicText": "Prior severe allergic reaction to Fluorouracil",
            "omopTable": "condition_occurrence",
            "timeConstraint": "prior",
            "strategy": "Identifies a history of severe allergy to Fluorouracil (5-FU), a component of the mFOLFOX6 regimen.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "partially_queryable",
            "clinicalConceptGroup": "mfolfox6_fluorouracil_contraindication"
          },
          {
            "nodeId": "1c",
            "nodeType": "atomic",
            "atomicText": "Prior severe allergic reaction to Oxaliplatin",
            "omopTable": "condition_occurrence",
            "timeConstraint": "prior",
            "strategy": "Identifies a history of severe allergy to Oxaliplatin, a component of the mFOLFOX6 regimen.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "partially_queryable",
            "clinicalConceptGroup": "mfolfox6_oxaliplatin_contraindication"
          },
          {
            "nodeId": "2a",
            "nodeType": "atomic",
            "atomicText": "Prior intolerance to Leucovorin",
            "omopTable": "condition_occurrence",
            "timeConstraint": "prior",
            "strategy": "Identifies a history of intolerance to Leucovorin (folinic acid), a component of the mFOLFOX6 regimen.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "partially_queryable",
            "clinicalConceptGroup": "mfolfox6_leucovorin_contraindication"
          },
          {
            "nodeId": "2b",
            "nodeType": "atomic",
            "atomicText": "Prior intolerance to Fluorouracil",
            "omopTable": "condition_occurrence",
            "timeConstraint": "prior",
            "strategy": "Identifies a history of intolerance to Fluorouracil (5-FU), a component of the mFOLFOX6 regimen.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "partially_queryable",
            "clinicalConceptGroup": "mfolfox6_fluorouracil_contraindication"
          },
          {
            "nodeId": "2c",
            "nodeType": "atomic",
            "atomicText": "Prior intolerance to Oxaliplatin",
            "omopTable": "condition_occurrence",
            "timeConstraint": "prior",
            "strategy": "Identifies a history of intolerance to Oxaliplatin, a component of the mFOLFOX6 regimen.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "partially_queryable",
            "clinicalConceptGroup": "mfolfox6_oxaliplatin_contraindication"
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 26,
        "textSnippet": "any component of study treatment.\n7. Subject has prior severe allergic reaction or intolerance to any component of mFOLFOX6.\n8. Subject has known dihydropyrimidine dehydrogenase deficiency (DPD). (NOTE: Screening \nfor DPD deficiency should be conducted per local requirements.)",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_8",
      "originalText": "Subject has known dihydropyrimidine dehydrogenase (DPD) deficiency. (NOTE: Screening for DPD deficiency should be conducted per local requirements.)",
      "type": "Exclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion is a single, positive condition identifying subjects with a known genetic deficiency. It is decomposed into a single atomic node. The parenthetical note is a procedural instruction for the site on how to screen for this condition, not a direct eligibility filter for the patient, and its context is captured in the strategy field.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "1",
        "nodeType": "atomic",
        "atomicText": "Known dihydropyrimidine dehydrogenase (DPD) deficiency",
        "omopTable": "condition_occurrence",
        "strategy": "This is a safety exclusion criterion. DPD deficiency is a genetic condition that can cause severe toxicity with certain chemotherapies (fluoropyrimidines). The note indicates that determination of this status is based on local screening procedures, which could involve genetic testing or enzyme activity assays.",
        "clinicalCategory": "safety_exclusion",
        "queryableStatus": "partially_queryable"
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 26,
        "textSnippet": "7. Subject has prior severe allergic reaction or intolerance to any component of mFOLFOX6.\n8. Subject has known dihydropyrimidine dehydrogenase deficiency (DPD). (NOTE: Screening \nfor DPD deficiency should be conducted per local requirements.)\n9. Subject has a complete gastric outlet syndrome or a partial gastric outlet syndrome with \npersistent/recurrent vomiting.",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_9",
      "originalText": "Subject has a complete gastric outlet syndrome or a partial gastric outlet syndrome with persistent/recurrent vomiting.",
      "type": "Exclusion",
      "logicOperator": "OR",
      "decompositionStrategy": "The criterion is decomposed using an OR operator to represent the two distinct pathways for eligibility. The first pathway is a single condition: having a complete gastric outlet syndrome. The second pathway is a compound condition, represented by an AND operator, requiring both a partial gastric outlet syndrome and persistent/recurrent vomiting.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "OR",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "atomic",
            "atomicText": "Complete gastric outlet syndrome",
            "omopTable": "condition_occurrence",
            "strategy": "Identify patients with a diagnosis of complete gastric outlet syndrome.",
            "clinicalCategory": "disease_indication",
            "queryableStatus": "fully_queryable",
            "clinicalConceptGroup": "gastric_outlet_syndrome"
          },
          {
            "nodeId": "2",
            "nodeType": "operator",
            "operator": "AND",
            "operands": [
              {
                "nodeId": "2a",
                "nodeType": "atomic",
                "atomicText": "Partial gastric outlet syndrome",
                "omopTable": "condition_occurrence",
                "strategy": "Identify patients with a diagnosis of partial gastric outlet syndrome.",
                "clinicalCategory": "disease_indication",
                "queryableStatus": "fully_queryable",
                "clinicalConceptGroup": "gastric_outlet_syndrome"
              },
              {
                "nodeId": "2b",
                "nodeType": "atomic",
                "atomicText": "Persistent or recurrent vomiting",
                "omopTable": "condition_occurrence",
                "strategy": "Identify patients with documented persistent or recurrent vomiting, which often requires chart review to confirm the pattern.",
                "clinicalCategory": "disease_indication",
                "queryableStatus": "partially_queryable"
              }
            ]
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 26,
        "textSnippet": "for DPD deficiency should be conducted per local requirements.)\n9. Subject has a complete gastric outlet syndrome or a partial gastric outlet syndrome with \npersistent/recurrent vomiting.\n10. Per investigator judgement, subject has significant gastric bleeding and/or untreated gastric \nulcers that exclude the subject from participation.",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_10",
      "originalText": "Per investigator judgment, subject has significant gastric bleeding and/or untreated gastric ulcers that would exclude the subject from participation per investigator judgment.",
      "type": "Exclusion",
      "logicOperator": "OR",
      "decompositionStrategy": "The criterion describes two conditions, 'significant gastric bleeding' and 'untreated gastric ulcers', linked by 'and/or', which is interpreted as an OR operator. The presence of either condition, as determined by investigator judgment, is sufficient for exclusion. This judgment-based nature makes both atomic conditions require manual review.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "OR",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "atomic",
            "atomicText": "Significant gastric bleeding",
            "omopTable": "condition_occurrence",
            "strategy": "This is a subjective assessment by the investigator to determine if any gastric bleeding is clinically significant enough to pose a safety risk for study participation.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "requires_manual"
          },
          {
            "nodeId": "2",
            "nodeType": "atomic",
            "atomicText": "Untreated gastric ulcers",
            "omopTable": "condition_occurrence",
            "strategy": "This is a subjective assessment by the investigator to confirm the presence of gastric ulcers and the absence of adequate, current treatment for them.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "requires_manual"
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 26,
        "textSnippet": "9. Subject has a complete gastric outlet syndrome or a partial gastric outlet syndrome with \npersistent/recurrent vomiting.\n10. Per investigator judgement, subject has significant gastric bleeding and/or untreated gastric \nulcers that exclude the subject from participation.\n11. Subject has a known history of a positive test for human immunodeficiency virus (HIV) \ninfection or known active hepatitis B (positive HBs Ag) or C infection. NOTE: Screening for \nthese infections should be conducted p...",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_11",
      "originalText": "Subject has a known history of a positive test for human immunodeficiency virus (HIV) infection or known active hepatitis B (positive HBs Ag) or C infection. NOTE: Screening for these infections should be conducted per local requirements.",
      "type": "Exclusion",
      "logicOperator": "OR",
      "decompositionStrategy": "The criterion is a disjunction of three independent conditions. A subject is eligible if they have a history of HIV, active Hepatitis B, OR active Hepatitis C. This is modeled as a root OR operator with three atomic operands.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "OR",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "atomic",
            "atomicText": "History of positive test for Human Immunodeficiency Virus (HIV) infection",
            "omopTable": "condition_occurrence",
            "strategy": "Identify patients with a documented diagnosis of HIV infection or a record of a positive HIV test.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "fully_queryable",
            "clinicalConceptGroup": "viral_infection_exclusion"
          },
          {
            "nodeId": "2",
            "nodeType": "atomic",
            "atomicText": "Active Hepatitis B infection (positive HBsAg)",
            "omopTable": "measurement",
            "valueConstraint": "positive Hepatitis B surface antigen (HBsAg) result",
            "strategy": "Identify patients with a positive lab result for Hepatitis B surface antigen (HBsAg), indicating active infection.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "fully_queryable",
            "clinicalConceptGroup": "viral_infection_exclusion"
          },
          {
            "nodeId": "3",
            "nodeType": "atomic",
            "atomicText": "Active Hepatitis C infection",
            "omopTable": "condition_occurrence",
            "strategy": "Identify patients with a documented diagnosis of Hepatitis C infection or a record of a positive test (e.g., HCV RNA).",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "fully_queryable",
            "clinicalConceptGroup": "viral_infection_exclusion"
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 26,
        "textSnippet": "10. Per investigator judgement, subject has significant gastric bleeding and/or untreated gastric \nulcers that exclude the subject from participation.\n11. Subject has a known history of a positive test for human immunodeficiency virus (HIV) \ninfection or known active hepatitis B (positive HBs Ag) or C infection. NOTE: Screening for \nthese infections should be conducted per local requirements. \na. For subjects who are negative for HBs Ag, but HBc Ab positive, an HB DNA test will \nbe performed ...",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_12",
      "originalText": "Subject has an active autoimmune disease that has required systemic treatment within the past 3 months prior to randomization.",
      "type": "Exclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion consists of three logically connected conditions: the presence of an active autoimmune disease, that this disease required systemic treatment, and that the treatment occurred within a specific time frame. This is modeled with an AND operator connecting the disease condition with a temporal node that wraps the treatment condition.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "AND",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "atomic",
            "atomicText": "Active autoimmune disease",
            "omopTable": "condition_occurrence",
            "strategy": "Identifies subjects with an ongoing autoimmune condition. The 'active' status is a clinical judgment and typically requires manual review.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "requires_manual"
          },
          {
            "nodeId": "2",
            "nodeType": "temporal",
            "temporalConstraint": {
              "operator": "WITHIN",
              "anchor": "randomization",
              "value": 3,
              "unit": "months"
            },
            "operand": {
              "nodeId": "2a",
              "nodeType": "atomic",
              "atomicText": "Required systemic treatment for autoimmune disease",
              "omopTable": "drug_exposure",
              "timeConstraint": "within the past 3 months prior to randomization",
              "timeFrameStructured": {
                "value": 3,
                "unit": "months",
                "operator": "within",
                "relativeEvent": "randomization"
              },
              "strategy": "Identifies use of systemic therapies (e.g., corticosteroids, biologics) which indicates the autoimmune disease was severe enough to require treatment recently.",
              "clinicalCategory": "safety_exclusion",
              "queryableStatus": "fully_queryable"
            }
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 26,
        "textSnippet": "c. Subjects treated with HCV with undetectable viral load results are eligible.\n12. Subject has an active autoimmune disease that has required systemic treatment within the past \n3 months prior to randomization.\n13. Subject has active infection requiring systemic therapy that has not completely resolved within \n7 days prior to randomization.",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_13",
      "originalText": "Subject has active infection requiring systemic therapy that has not completely resolved within 7 days prior to randomization.",
      "type": "Exclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion describes a single exclusionary condition composed of three parts, all of which must be true: the presence of an active infection, the requirement for systemic therapy, and the lack of complete resolution within a specific timeframe. This is modeled as an AND of these three conditions, with the 'not completely resolved' part explicitly captured using a NOT operator nested within a temporal constraint.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "AND",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "atomic",
            "atomicText": "Active infection",
            "omopTable": "condition_occurrence",
            "strategy": "Identifies a current diagnosis of an infectious disease.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "fully_queryable"
          },
          {
            "nodeId": "2",
            "nodeType": "atomic",
            "atomicText": "Requires systemic therapy for infection",
            "omopTable": "drug_exposure",
            "strategy": "Identifies the use of systemic anti-infective medications (e.g., IV antibiotics, oral antivirals), which implies the infection is significant.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "fully_queryable"
          },
          {
            "nodeId": "3",
            "nodeType": "temporal",
            "temporalConstraint": {
              "operator": "WITHIN",
              "anchor": "randomization",
              "value": 7,
              "unit": "days"
            },
            "operand": {
              "nodeId": "3a",
              "nodeType": "operator",
              "operator": "NOT",
              "operands": [
                {
                  "nodeId": "3a1",
                  "nodeType": "atomic",
                  "atomicText": "Infection has completely resolved",
                  "omopTable": "observation",
                  "strategy": "Checks for the absence of a documented resolution of the infection within the 7-day window prior to randomization. This is typically a clinical assessment found in notes.",
                  "clinicalCategory": "safety_exclusion",
                  "queryableStatus": "requires_manual"
                }
              ]
            }
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 26,
        "textSnippet": "12. Subject has an active autoimmune disease that has required systemic treatment within the past \n3 months prior to randomization.\n13. Subject has active infection requiring systemic therapy that has not completely resolved within \n7 days prior to randomization.",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_14",
      "originalText": "Subject has significant cardiovascular disease, including any of the following:",
      "type": "Exclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion is a single high-level statement that acts as a header for a list of specific conditions. The phrase 'including any of the following' indicates that this general condition is met if at least one of the (unlisted) specific conditions is true, implying an OR relationship among those specifics. Since the specific conditions are not provided, the header itself is modeled as a single atomic node representing the overall exclusion for 'significant cardiovascular disease'.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "1",
        "nodeType": "atomic",
        "atomicText": "Significant cardiovascular disease",
        "omopTable": "condition_occurrence",
        "strategy": "This is a general exclusion category for patients with significant cardiovascular risk. The specific conditions that qualify under this category would be listed subsequently and would form an OR group.",
        "clinicalCategory": "safety_exclusion",
        "queryableStatus": "partially_queryable",
        "clinicalConceptGroup": "significant_cardiovascular_disease"
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 65,
        "textSnippet": "13. Subject has active infection requiring systemic therapy that has not completely \nresolved within 7 days prior to randomization.\n14. Subject has significant cardiovascular disease, including any of the following:",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_15",
      "originalText": "Subject has history of central nervous system metastases and/or carcinomatous meningitis from gastric/GEJ cancer.",
      "type": "Exclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion requires a history of specific central nervous system involvement (CNS metastases or carcinomatous meningitis) that originates from a specific primary cancer (gastric or GEJ). This is best modeled as a top-level AND condition: the patient must have a diagnosis for the primary cancer AND a diagnosis for the CNS involvement. Both the primary cancer and CNS involvement clauses are decomposed into OR groups.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "AND",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "operator",
            "operator": "OR",
            "operands": [
              {
                "nodeId": "1a",
                "nodeType": "atomic",
                "atomicText": "History of gastric cancer",
                "omopTable": "condition_occurrence",
                "strategy": "Identifies the primary malignancy as gastric cancer. This is required as the origin for the CNS condition.",
                "clinicalCategory": "disease_indication",
                "queryableStatus": "fully_queryable",
                "clinicalConceptGroup": "gastric_gej_cancer"
              },
              {
                "nodeId": "1b",
                "nodeType": "atomic",
                "atomicText": "History of gastroesophageal junction (GEJ) cancer",
                "omopTable": "condition_occurrence",
                "strategy": "Identifies the primary malignancy as GEJ cancer. This is required as the origin for the CNS condition.",
                "clinicalCategory": "disease_indication",
                "queryableStatus": "fully_queryable",
                "clinicalConceptGroup": "gastric_gej_cancer"
              }
            ]
          },
          {
            "nodeId": "2",
            "nodeType": "operator",
            "operator": "OR",
            "operands": [
              {
                "nodeId": "2a",
                "nodeType": "atomic",
                "atomicText": "History of central nervous system metastases",
                "omopTable": "condition_occurrence",
                "strategy": "Identifies one of the required types of CNS involvement.",
                "clinicalCategory": "disease_indication",
                "queryableStatus": "fully_queryable",
                "clinicalConceptGroup": "cns_involvement"
              },
              {
                "nodeId": "2b",
                "nodeType": "atomic",
                "atomicText": "History of carcinomatous meningitis",
                "omopTable": "condition_occurrence",
                "strategy": "Identifies the second possible type of required CNS involvement.",
                "clinicalCategory": "disease_indication",
                "queryableStatus": "fully_queryable",
                "clinicalConceptGroup": "cns_involvement"
              }
            ]
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 66,
        "textSnippet": "e. Cardiac arrhythmias requiring anti-arrhythmic medications (Subject with rate \ncontrolled atrial fibrillation for > 1 month prior to randomization are eligible).\n15. Subject has history of central nervous system metastases and/or carcinomatous \nmeningitis from gastric/GEJ cancer. \n16. Subject has known peripheral sensory neuropathy > grade 1 unless the absence of \ndeep tendon reflexes is the sole neurological abnormality.",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_16",
      "originalText": "Subject has known peripheral sensory neuropathy > grade 1 unless the absence of deep tendon reflexes is the sole neurological abnormality.",
      "type": "Exclusion",
      "logicOperator": "EXCEPT",
      "decompositionStrategy": "The criterion follows an 'A unless B' structure, which is best represented by the EXCEPT operator: EXCEPT(A, B). 'A' is the primary condition (neuropathy > grade 1). 'B' is the exception, which requires two conditions to be met simultaneously (AND logic): (1) the 'absence of' deep tendon reflexes and (2) this being the 'sole' abnormality, implying the absence of others. Both of these sub-conditions are negations and are modeled using the NOT operator.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "EXCEPT",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "atomic",
            "atomicText": "Peripheral sensory neuropathy grade > 1",
            "omopTable": "observation",
            "numericConstraintStructured": {
              "value": 1,
              "operator": ">",
              "unit": "",
              "parameter": "Peripheral sensory neuropathy grade (e.g., CTCAE)"
            },
            "strategy": "Identifies patients with clinically significant peripheral sensory neuropathy.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "requires_manual",
            "clinicalConceptGroup": "peripheral_neuropathy"
          },
          {
            "nodeId": "2",
            "nodeType": "operator",
            "operator": "AND",
            "operands": [
              {
                "nodeId": "2a",
                "nodeType": "operator",
                "operator": "NOT",
                "operands": [
                  {
                    "nodeId": "2a1",
                    "nodeType": "atomic",
                    "atomicText": "Deep tendon reflexes present",
                    "omopTable": "observation",
                    "strategy": "This node identifies the presence of DTRs. The parent NOT operator negates it to find subjects with an 'absence of' DTRs.",
                    "clinicalCategory": "safety_exclusion",
                    "queryableStatus": "requires_manual"
                  }
                ]
              },
              {
                "nodeId": "2b",
                "nodeType": "operator",
                "operator": "NOT",
                "operands": [
                  {
                    "nodeId": "2b1",
                    "nodeType": "atomic",
                    "atomicText": "Other neurological abnormality present",
                    "omopTable": "condition_occurrence",
                    "strategy": "This node identifies any other neurological abnormalities. The parent NOT operator negates it, ensuring that the absence of DTRs is the 'sole' finding.",
                    "clinicalCategory": "safety_exclusion",
                    "queryableStatus": "requires_manual"
                  }
                ]
              }
            ]
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 66,
        "textSnippet": "meningitis from gastric/GEJ cancer. \n16. Subject has known peripheral sensory neuropathy > grade 1 unless the absence of \ndeep tendon reflexes is the sole neurological abnormality. \n17. Subject has had a major surgical procedure \uf0a3 28 days prior to randomization. \na. Subject is without complete recovery from a major surgical procedure \uf0a3 14 days \nprior to randomization.",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_17",
      "originalText": "Subject has had a major surgical procedure \u2264 28 days prior to randomization.",
      "type": "Exclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion describes a single event ('major surgical procedure') occurring within a specific time frame ('\u2264 28 days prior to randomization'). This is represented by a temporal node wrapping an atomic node. The temporal node captures the time constraint, and the nested atomic node represents the core clinical event.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "1",
        "nodeType": "temporal",
        "temporalConstraint": {
          "operator": "WITHIN",
          "anchor": "randomization",
          "value": 28,
          "unit": "days"
        },
        "operand": {
          "nodeId": "1a",
          "nodeType": "atomic",
          "atomicText": "Had a major surgical procedure",
          "omopTable": "procedure_occurrence",
          "strategy": "This criterion excludes patients who have recently undergone major surgery, as this could confound the assessment of adverse events or affect the patient's ability to tolerate the study treatment. Defining 'major' surgery may require a specific list of procedure codes.",
          "clinicalCategory": "safety_exclusion",
          "queryableStatus": "partially_queryable"
        }
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 66,
        "textSnippet": "deep tendon reflexes is the sole neurological abnormality. \n17. Subject has had a major surgical procedure \uf0a3 28 days prior to randomization. \na. Subject is without complete recovery from a major surgical procedure \uf0a3 14 days \nprior to randomization.\n18. Subject has psychiatric illness or social situations that would preclude study \ncompliance, per investigator judgment.",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_18",
      "originalText": "Subject has psychiatric illness or social situations that would preclude study compliance, per investigator judgment.",
      "type": "Exclusion",
      "logicOperator": "OR",
      "decompositionStrategy": "The criterion is a simple OR condition. The subject is ineligible if they meet either of the two specified conditions: having a psychiatric illness or social situations that would interfere with study compliance. Both conditions are subject to the investigator's judgment, making them manual assessments.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "OR",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "atomic",
            "atomicText": "Psychiatric illness that would preclude study compliance per investigator judgment",
            "omopTable": "condition_occurrence",
            "strategy": "This is a subjective assessment by the investigator to exclude patients whose psychiatric conditions would make it difficult or unsafe for them to adhere to the study protocol.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "requires_manual"
          },
          {
            "nodeId": "2",
            "nodeType": "atomic",
            "atomicText": "Social situations that would preclude study compliance per investigator judgment",
            "omopTable": "observation",
            "strategy": "This is a subjective assessment by the investigator to exclude patients whose social circumstances (e.g., unstable housing, lack of support) would prevent them from reliably participating in the study.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "requires_manual"
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 66,
        "textSnippet": "a. Subject is without complete recovery from a major surgical procedure \uf0a3 14 days \nprior to randomization.\n18. Subject has psychiatric illness or social situations that would preclude study \ncompliance, per investigator judgment.\n19. Subject has another malignancy for which treatment is required per investigator\u2019s \nclinical judgment.",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_19",
      "originalText": "Subject has another malignancy for which treatment is required per investigator\u2019s clinical judgment.",
      "type": "Exclusion",
      "logicOperator": "AND",
      "decompositionStrategy": "The criterion is a single, indivisible condition that describes the presence of a concurrent malignancy requiring active treatment. This is represented as a single atomic node, as there are no boolean operators connecting multiple clauses. The phrase 'per investigator\u2019s clinical judgment' indicates that this condition requires manual assessment.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "1",
        "nodeType": "atomic",
        "atomicText": "Another malignancy for which treatment is required",
        "omopTable": "condition_occurrence",
        "strategy": "This criterion excludes subjects with a concurrent cancer requiring active treatment, as this could confound the assessment of the study treatment's efficacy or safety. The determination of whether treatment is required is based on the investigator's clinical judgment.",
        "clinicalCategory": "safety_exclusion",
        "queryableStatus": "requires_manual"
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 66,
        "textSnippet": "18. Subject has psychiatric illness or social situations that would preclude study \ncompliance, per investigator judgment.\n19. Subject has another malignancy for which treatment is required per investigator\u2019s \nclinical judgment. \n20. Subject has any concurrent disease, infection or comorbid condition that interferes \nwith the ability of the subject to participate in the study, which places the subject at \nundue risk or complicates the interpretation of data in the opinion of the investigator.",
        "confidence": 1.0
      }
    },
    {
      "criterionId": "EXC_20",
      "originalText": "Subject has any concurrent disease, infection or comorbid condition that interferes with the ability of the subject to participate in the study, which places the subject at undue risk or complicates the interpretation of data in the opinion of the investigator.",
      "type": "Exclusion",
      "logicOperator": "OR",
      "decompositionStrategy": "The criterion describes three distinct disqualifying characteristics of a concurrent condition, linked by an 'OR' relationship. The entire judgment is subjective ('in the opinion of the investigator'). Therefore, the structure is an OR operator with three atomic operands, each representing one of the reasons for exclusion, and all are marked as requiring manual review.",
      "hasNestedLogic": true,
      "expression": {
        "nodeId": "root",
        "nodeType": "operator",
        "operator": "OR",
        "operands": [
          {
            "nodeId": "1",
            "nodeType": "atomic",
            "atomicText": "Concurrent disease, infection or comorbid condition that interferes with the ability of the subject to participate in the study",
            "omopTable": "observation",
            "strategy": "This is a general safety exclusion based on investigator judgment. It covers any condition that makes study participation physically or logistically difficult or impossible for the subject.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "requires_manual"
          },
          {
            "nodeId": "2",
            "nodeType": "atomic",
            "atomicText": "Concurrent disease, infection or comorbid condition that places the subject at undue risk",
            "omopTable": "observation",
            "strategy": "This is a general safety exclusion based on investigator judgment. It covers any condition that would make participation in the study unacceptably dangerous for the subject.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "requires_manual"
          },
          {
            "nodeId": "3",
            "nodeType": "atomic",
            "atomicText": "Concurrent disease, infection or comorbid condition that complicates the interpretation of data",
            "omopTable": "observation",
            "strategy": "This is a general exclusion to protect study integrity, based on investigator judgment. It covers any condition that could act as a confounding factor, making it difficult to attribute outcomes to the study intervention.",
            "clinicalCategory": "safety_exclusion",
            "queryableStatus": "requires_manual"
          }
        ]
      },
      "useExpressionTree": true,
      "provenance": {
        "pageNumber": 66,
        "textSnippet": "19. Subject has another malignancy for which treatment is required per investigator\u2019s \nclinical judgment. \n20. Subject has any concurrent disease, infection or comorbid condition that interferes \nwith the ability of the subject to participate in the study, which places the subject at \nundue risk or complicates the interpretation of data in the opinion of the investigator.",
        "confidence": 1.0
      }
    }
  ],
  "counts": {
    "criteria": 37,
    "atomics": 110,
    "options": 0
  },
  "errors": []
}